Preclinical mouse models suggest that the gut microbiome modulates tumor response to
checkpoint blockade immunotherapy; however, this has not been well-characterized in human …

Gut bacteria modulate the response to immune checkpoint blockade (ICB) treatment in cancer,
but the effect of diet and supplements on this interaction is not well studied. We assessed …

Abstract Treatment with immune checkpoint blockade (ICB) has revolutionized cancer therapy.
Until now, predictive biomarkers 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 – 10 and strategies to augment …

The microbiome is receiving significant attention given its influence on a host of human
diseases including cancer. Its role in response to cancer treatment is becoming increasingly …

Immune checkpoint blockade represents a major breakthrough in cancer therapy; however,
responses are not universal. Genomic and immune features in pretreatment tumor biopsies …

Abstract Treatment with combined immune checkpoint blockade (CICB) targeting CTLA-4 and
PD-1 is associated with clinical benefit across tumor types, but also a high rate of immune-…

Immune checkpoint blockade produces clinical benefit in many patients. However, better
biomarkers of response are still needed, and mechanisms of resistance remain incompletely …

Preclinical studies suggest that treatment with neoadjuvant immune checkpoint blockade is
associated with enhanced survival and antigen-specific T cell responses compared with …

OBJECTIVE: To evaluate the performance of a one-stop multidisciplinary clinic of screening
for fetal chromosomal anomalies in the first trimester of pregnancy by a combination of …

Background Obesity has been linked to increased mortality in several cancer types; however,
the relation between obesity and survival outcomes in metastatic melanoma is unknown. …